Table 1.
Baseline demographical and clinical characteristics in patients with low-energy distal radius fracture and controls who visited the osteoporosis centre at both inclusion and at one year follow up.
| Distal radius fracture | Controls | p* | |
| n = 160 | n = 169 | ||
| Demographics | |||
| Age (years; mean (SD)) | 67 (9) | 66 (9) | 0.457 |
| Females | 144 (90) | 151 (89) | 0.846 |
| BMI (kg/m2) | 25.7 (4.3) | 26.7 (4.3) | 0.027 |
| Menarche (years; mean (SD)) | 13.9 (1.5) | 13.6 (1.4) | 0.066 |
| Menopause (years; mean (SD)) | 48.9 (4.5) | 49.6 (4.1) | 0.086 |
| Education | 0.011 | ||
| < 10 years | 56 (38) | 70 (42) | |
| 11–13 years | 61 (42) | 45 (27) | |
| > 13 years | 30 (20) | 53 (31) | |
| Co-habiting | 84(53) | 112 (67) | 0.011 |
| Regular exercise** | 119 (74) | 126 (74) | 0.970 |
| Current smoker | 23 (14) | 21 (12) | 0.604 |
| Clinical characteristics | |||
| Current calcium and/or vitamin D treatment | 39 (24) | 41 (24) | 0.981 |
| Current ART | 28 (18) | 22 (13) | 0.258 |
| Previous fractures | 83 (52) | 77 (47) | 0.319 |
| ≥ 1 fall in the previous year | 68 (47) | 48 (36) | 0.054 |
| Osteoporosis | 52 (32) | 30 (18) | <0.001 |
| Osteopenia | 83 (52) | 74 (44) | |
| Normal BMD | 25 (16) | 64 (38) | |
| Heart diseases | 48 (30) | 58 (34) | 0.402 |
| Pulmonary diseases | 19 (12) | 12 (7) | 0.138 |
| Neurological diseases | 12 (8) | 14 (8) | 0.792 |
| Endocrine disorders | 14 (9) | 20 (12) | 0.358 |
| Gastrointestinal disorders | 8 (5) | 21 (12) | 0.018 |
| Urogenital disorders | 5 (3) | 1 (1) | 0.086 |
| Inflammatory joint disorders and connective tissue disorders | 36 (23) | 45 (26) | 0.385 |
| Cancer | 16 (10) | 19 (11) | 0.715 |
| Mental disorders | 7 (4) | 11 (7) | 0.395 |
| Co-morbidities (range 0–6) | 1.0 (1.0) | 1.2 (1.1) | 0.191 |
Mean (SD) for continuous variables and numbers (%) for categorical variables.
*Bold p-values indicate significant differences between the groups
** Exercise more than 30 minutes three times a week.
BMI, body mass index; ART, antiresorptive treatment, a specific osteoporosis treatment comprising biphosphonates, or selective oestrogen-receptor modulators.